Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137690891> ?p ?o ?g. }
- W2137690891 endingPage "75" @default.
- W2137690891 startingPage "69" @default.
- W2137690891 abstract "Prolonged exposure to topotecan in in vitro and in vivo experiments has yielded the highest antitumor efficacy. An oral formulation of topotecan with a bioavailability of 32-44% in humans enables convenient prolonged administration. Pharmacokinetic/pharmacodynamic relationships from four Phase I studies with different schedules of administration of oral topotecan in 99 adult patients with malignant solid tumors refractory to standard forms of chemotherapy were compared. Topotecan was administered as follows: (a) once daily (o.d.) for 5 days every 21 days (29 patients); (b) o.d. for 10 days every 21 days (19 patients); (c) twice daily (b.i.d.) for 10 days every 21 days (20 patients); and (d) b.i.d. for 21 days every 28 days (31 patients). Pharmacokinetic analysis was performed in 55 patients using a validated high-performance liquid chromatographic assay and noncompartmental pharmacokinetic methods. Totals of 109, 48, 64, and 59 courses were given, respectively. Dose-limiting toxicity consisted of granulocytopenia for the o.d. x 5-day dosage, a combination of myelosuppression and diarrhea in both of the 10-day schedules, and only diarrhea in the 21-day schedule. Pharmacokinetics revealed a substantial variation of the area under curve (AUC) of topotecan lactone in all of the dose schedules with a mean intrapatient variation of 25.4 +/- 31.0% (o.d. x 5), 34.5 +/- 25.0% (o.d. x 10), 96.5 +/- 70.1% (b.i.d. x 10), and 59.5 +/- 51.0% (b.i.d. x 21). Significant correlations were observed between myelotoxicity parameters and AUC(t) day 1 and AUC(t) per course of topotecan lactone. In all of the studies, similar sigmoidal relationships could be established between AUC(t) per course and the percentage decrease of WBCs. At maximum-tolerated dose level, no significant difference in AUC(t) per course was found [AUC(t) per course was 107.4 +/- 33.7 ng x h/ml (o.d. x 5), 145.3 +/- 23.8 ng x h/ml (o.d. x 10), 100.0 +/- 41.5 ng x h/ml (b.i.d. x 10), and 164.9 +/- 92.2 ng x h/ml (b.i.d. x 21), respectively.] For oral topotecan, the schedule rather than the AUC(t)-per-course seemed to be related to the type of toxicity. Prolonged oral administration resulted in intestinal side effects as a dose-limiting toxicity, and short-term administration resulted in granulocytopenia. On the basis of this pharmacokinetic study, no schedule preference could be expressed, but based on patient convenience, administration once daily for 5 days could be favored." @default.
- W2137690891 created "2016-06-24" @default.
- W2137690891 creator A5000418012 @default.
- W2137690891 creator A5002774834 @default.
- W2137690891 creator A5011819733 @default.
- W2137690891 creator A5014910217 @default.
- W2137690891 creator A5021449457 @default.
- W2137690891 creator A5042674500 @default.
- W2137690891 creator A5052540642 @default.
- W2137690891 creator A5067526861 @default.
- W2137690891 creator A5071938679 @default.
- W2137690891 creator A5072308451 @default.
- W2137690891 creator A5080900202 @default.
- W2137690891 creator A5091656720 @default.
- W2137690891 date "1999-01-01" @default.
- W2137690891 modified "2023-09-23" @default.
- W2137690891 title "A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)" @default.
- W2137690891 cites W1536538430 @default.
- W2137690891 cites W176068902 @default.
- W2137690891 cites W1831044128 @default.
- W2137690891 cites W1883759477 @default.
- W2137690891 cites W1913802169 @default.
- W2137690891 cites W1919288105 @default.
- W2137690891 cites W1952453258 @default.
- W2137690891 cites W1981987977 @default.
- W2137690891 cites W1995024307 @default.
- W2137690891 cites W2028269517 @default.
- W2137690891 cites W2034706703 @default.
- W2137690891 cites W2048838221 @default.
- W2137690891 cites W2051996555 @default.
- W2137690891 cites W2056333272 @default.
- W2137690891 cites W2066933615 @default.
- W2137690891 cites W2067024881 @default.
- W2137690891 cites W2071874725 @default.
- W2137690891 cites W2073985236 @default.
- W2137690891 cites W2078865702 @default.
- W2137690891 cites W2091111837 @default.
- W2137690891 cites W2092998745 @default.
- W2137690891 cites W2108018389 @default.
- W2137690891 cites W2159921901 @default.
- W2137690891 cites W2255443552 @default.
- W2137690891 cites W2277082935 @default.
- W2137690891 cites W2323954108 @default.
- W2137690891 cites W2414246616 @default.
- W2137690891 cites W2415680948 @default.
- W2137690891 cites W2442148339 @default.
- W2137690891 cites W2913333263 @default.
- W2137690891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9918204" @default.
- W2137690891 hasPublicationYear "1999" @default.
- W2137690891 type Work @default.
- W2137690891 sameAs 2137690891 @default.
- W2137690891 citedByCount "21" @default.
- W2137690891 countsByYear W21376908912015 @default.
- W2137690891 countsByYear W21376908912023 @default.
- W2137690891 crossrefType "journal-article" @default.
- W2137690891 hasAuthorship W2137690891A5000418012 @default.
- W2137690891 hasAuthorship W2137690891A5002774834 @default.
- W2137690891 hasAuthorship W2137690891A5011819733 @default.
- W2137690891 hasAuthorship W2137690891A5014910217 @default.
- W2137690891 hasAuthorship W2137690891A5021449457 @default.
- W2137690891 hasAuthorship W2137690891A5042674500 @default.
- W2137690891 hasAuthorship W2137690891A5052540642 @default.
- W2137690891 hasAuthorship W2137690891A5067526861 @default.
- W2137690891 hasAuthorship W2137690891A5071938679 @default.
- W2137690891 hasAuthorship W2137690891A5072308451 @default.
- W2137690891 hasAuthorship W2137690891A5080900202 @default.
- W2137690891 hasAuthorship W2137690891A5091656720 @default.
- W2137690891 hasConcept C111113717 @default.
- W2137690891 hasConcept C112705442 @default.
- W2137690891 hasConcept C121332964 @default.
- W2137690891 hasConcept C126322002 @default.
- W2137690891 hasConcept C142424586 @default.
- W2137690891 hasConcept C181389837 @default.
- W2137690891 hasConcept C2776694085 @default.
- W2137690891 hasConcept C2777056448 @default.
- W2137690891 hasConcept C2779802037 @default.
- W2137690891 hasConcept C2781209748 @default.
- W2137690891 hasConcept C29730261 @default.
- W2137690891 hasConcept C71924100 @default.
- W2137690891 hasConcept C76318530 @default.
- W2137690891 hasConcept C87355193 @default.
- W2137690891 hasConcept C90924648 @default.
- W2137690891 hasConcept C98274493 @default.
- W2137690891 hasConceptScore W2137690891C111113717 @default.
- W2137690891 hasConceptScore W2137690891C112705442 @default.
- W2137690891 hasConceptScore W2137690891C121332964 @default.
- W2137690891 hasConceptScore W2137690891C126322002 @default.
- W2137690891 hasConceptScore W2137690891C142424586 @default.
- W2137690891 hasConceptScore W2137690891C181389837 @default.
- W2137690891 hasConceptScore W2137690891C2776694085 @default.
- W2137690891 hasConceptScore W2137690891C2777056448 @default.
- W2137690891 hasConceptScore W2137690891C2779802037 @default.
- W2137690891 hasConceptScore W2137690891C2781209748 @default.
- W2137690891 hasConceptScore W2137690891C29730261 @default.
- W2137690891 hasConceptScore W2137690891C71924100 @default.
- W2137690891 hasConceptScore W2137690891C76318530 @default.
- W2137690891 hasConceptScore W2137690891C87355193 @default.
- W2137690891 hasConceptScore W2137690891C90924648 @default.